Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts
The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.
Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns
The makers of several PARP inhibitors shared data they said support using these drugs with anti-androgen therapy in all advanced prostate cancer patients, but oncologists want more biomarker data.
Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors
New exploratory findings suggest second-line treatment with Deciphera Pharmaceuticals' Qinlock could benefit GIST patients with specific KIT resistance mutations.
Astellas' Zolbetuximab Plus Chemo Benefits CLDN18.2-Positive, HER2-Negative Gastric Cancer Patients
In the first-line treatment setting, the investigational agent plus chemo led to improved survival outcomes versus chemotherapy alone, according to new Phase III data.
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.